Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases

被引：0
|
作者：
Li, Y. -B. [1 ]
机构：
[1] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
T790M-negative EGFR-mutant NSCLC; Brain and leptomeningeal metastases; Aumolertinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-56
引用
收藏
页码：S663 / S664
页数：2
相关论文
共 50 条
  • [1] Efficacy of Aumolertinib in EGFR T790M-negative or -unknown NSCLC with Brain Metastases Following Resistance to Prior EGFR-TKIs
    Han, C. B.
    Dai, Z. X.
    Jin, B.
    Cui, W.
    Man, L.
    Zhang, H. J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S341 - S341
  • [2] Osimertinib for EGFR-Positive NSCLC Patients with Leptomeningeal Metastases Harboring T790M-Positive or T790M-Negative Mutations
    Xu, H.
    Zhang, Y.
    Kong, J.
    Yang, G.
    Yang, L.
    Liu, S.
    Wang, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S612 - S613
  • [3] High-dose aumolertinib versus osimertinib in EGFR T790M+NSCLC patients with brain metastases (ATTACK)
    Lu, S.
    Han, L.
    Lv, D.
    Zhang, Z.
    Wu, J.
    Wang, Q.
    Dong, X.
    Hu, Y.
    Chen, J.
    Wu, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S86 - S86
  • [4] High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVE
    Fan, Y.
    Zhu, J.
    He, J.
    Zhou, R.
    Chen, J.
    Han, G.
    Ren, B. Y.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1585 - S1585
  • [5] Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease
    Arulananda, Surein
    Do, Hongdo
    Rivalland, Gareth
    Loh, Zoe
    Musafer, Ashan
    Lau, Eddie
    Mitchell, Paul
    Dobrovic, Alexander
    John, Thomas
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 (05) : 1756 - 1764
  • [6] Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.
    Liu, Stephen V.
    Aggarwal, Charu
    Brzezniak, Christina
    Doebele, Robert Charles
    Gerber, David E.
    Gitlitz, Barbara
    Horn, Leora
    Solomon, Benjamin J.
    Stinchcombe, Tom
    Villaruz, Liza Cosca
    West, Howard Jack
    Kroll, Stew
    Pearce, Tillman E.
    Camidge, D. Ross
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure
    Ding, H.
    Xu, T.
    Wang, X.
    Cheng, W.
    Fang, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S670 - S671
  • [8] A Phase 2 Study of TH-4000 in Patients with EGFR Mutant, T790M-Negative, Advanced NSCLC Progressing on an EGFR TKI
    Liu, Stephen V.
    Aggarawal, Charu
    Carter, Corey
    Gerber, David E.
    Gitlitz, Barbara J.
    Horn, Leora
    Solomon, Benjamin J.
    Stinchcombe, Thomas E.
    Villaruz, Liza
    West, Howard
    Kroll, Stew
    Pearce, Tillman
    Carnidge, Ross
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S429 - S430
  • [9] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [10] Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
    Shigeki Nanjo
    Akito Hata
    Chiyuki Okuda
    Reiko Kaji
    Hideaki Okada
    Daisuke Tamura
    Kei Irie
    Hiroshi Okada
    Shoji Fukushima
    Nobuyuki Katakami
    [J]. British Journal of Cancer, 2018, 118 : 32 - 37
12345